Filtered By:
Drug: Estradiol
Therapy: Hormonal Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study
Estrogen therapy is prescribed for women without a uterus. For women with intact uteri, progestogens should be added to protect against endometrial hyperplasia. Different estrogen profiles may cause different side effects and beneficial clinical outcomes [1]. Different forms of estrogen also have different serum E2 concentrations; a previous study demonstrated that 1  mg E2 was equivalent to 0.4 mg CEE [1]. Progestin includes medroxyprogesterone acetate (MPA) and norethindrone acetate (NE). In Taiwan, the most common MHT for patients with an intact uterus are CEE (0.625 mg) or E2 (2 mg) combined with 5 mg MPA or 1 mg NE [2,3].
Source: Maturitas - August 1, 2022 Category: Primary Care Authors: Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding Tags: Original article Source Type: research

Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
CONCLUSIONS: Although HT continues to have an important role in menopause management, it is not recommended for primary or secondary CVD prevention. Different formulations, doses, and routes of delivery of HT have different effects on cardiometabolic markers and risks of clinical CVD events. However, long-term trials evaluating clinical outcomes with transdermal and other alternate HT regimens are limited. PMID: 33506261 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - January 28, 2021 Category: Endocrinology Authors: Shufelt CL, Manson JE Tags: J Clin Endocrinol Metab Source Type: research

Loss of Estrogen Efficacy Against Hippocampus Damage in Long-Term OVX Mice Is Related to the Reduction of Hippocampus Local Estrogen Production and Estrogen Receptor Degradation
AbstractPostmenopausal women experience a higher risk for neurodegenerative diseases, including cognitive impairment and ischemic stroke. Many preclinical studies have indicated that estrogen replacement therapy (ERT) may provide protective effects against these neurological diseases. However, the results of Women ’s Health Initiative (WHI) studies have led to the proposal of “critical period hypothesis,” which states that there is a precise window of opportunity for administering beneficial hormone therapy following menopause. However, the underlying molecular mechanisms require further characterizatio n. Here, we e...
Source: Molecular Neurobiology - June 14, 2020 Category: Neurology Source Type: research

The critical period for neuroprotection by estrogen replacement therapy and the potential underlying mechanisms.
Abstract 17β-Estradiol (estradiol or E2) is a steroid hormone that has been broadly applied as a neuroprotective therapeutic for a variety of neurodegenerative and cerebrovascular disorders such as ischemic stroke, Alzheimer's disease, and Parkinson's disease. Several laboratory and clinical studies have reported that estrogen replacement therapy (ERT) had no effect against these diseases in elderly postmenopausal women, and at worst, increased their risk of onset and mortality. This review focuses on the growing body of data from in vitro and animal models characterizing the potential underlying mechanisms and s...
Source: Current Neuropharmacology - January 22, 2020 Category: Drugs & Pharmacology Authors: Guo H, Liu M, Zhang L, Wang L, Hou W, Ma Y, Ma Y Tags: Curr Neuropharmacol Source Type: research

Sex Differences in Sex Hormone Profiles and Prediction of Consciousness Recovery After Severe Traumatic Brain Injury
Conclusion: These findings indicate that TBI differentially affects the levels of sex-steroid hormones in men and women patients. Plasma levels of testosterone could be a good candidate blood marker to predict recovery from unconsciousness after sTBI for male patients. Introduction Traumatic brain injury (TBI) is a major cause of death and disability worldwide and is increasing in incidence (1). Patients with acute severe TBI (sTBI) often develop severe disorders of consciousness, i.e., coma, minimally conscious state or vegetative state. Although many patients may regain consciousness during the 1-month post-TBI p...
Source: Frontiers in Endocrinology - April 25, 2019 Category: Endocrinology Source Type: research

Stroke Characteristics, Risk Factors, and Outcomes in Transgender Adults: A Case Series
Conclusions: Understanding unique vulnerabilities of the transgender community for cerebrovascular events is essential to provide culturally appropriate counseling for harm reduction.
Source: The Neurologist - March 1, 2019 Category: Neurology Tags: Case Report/Case Series Source Type: research

Impact of microbiota on the use and effects of isoflavones in the relief of climacteric symptoms in menopausal women – A review
Publication date: February 2018 Source:Journal of Functional Foods, Volume 41 Author(s): Naice E.S. Monteiro, Lívia D. Queirós, Danielle B. Lopes, Adriana O. Pedro, Gabriela A. Macedo Menopause is a natural event that occurs in women around the age of 50 years, causing irregularities in the menstrual cycle until its complete end, due to the hormonal deficit, especially estrogen, that causes several unpleasant urogenital and vasomotor symptoms. Hormone replacement therapy has many benefits, but should be prescribed with caution in women with a history of stroke, thromboembolic events, certain types of cancer, or increa...
Source: Journal of Functional Foods - December 22, 2017 Category: Nutrition Source Type: research

Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review
ConclusionsEvidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.
Source: Endocrine - October 16, 2017 Category: Endocrinology Source Type: research

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrease the risk of strok...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.
Abstract Wide rejection of conventional hormone therapy (HT) after the initial publication of the Women's Health Initiative (WHI) led to unjustified use of custom-compounded bioidentical hormones. In the USA, it became an unregulated drug manufacturer industry in disguise, without proper control and making false claims and misleading advertisements. Manufacturing quality is not ensured. Unspecific harm from compounding has occurred on a large scale, such as deaths from infected products and end-stage renal failure plus carcinoma due to confusion between different Chinese herbs. Oral estrogens increase venous throm...
Source: Climacteric - May 18, 2017 Category: Geriatrics Authors: L'Hermite M Tags: Climacteric Source Type: research

SIRT1-dependent AMPK pathway in the protection of estrogen against ischemic brain injury.
CONCLUSION: Our data support that estrogen protects against ischemic stroke through preventing neuron death via the SIRT1-dependent AMPK pathway. PMID: 28256111 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - March 1, 2017 Category: Neuroscience Authors: Guo JM, Shu H, Wang L, Xu JJ, Niu XC, Zhang L Tags: CNS Neurosci Ther Source Type: research

Bioidentical hormones for women with vasomotor symptoms.
CONCLUSIONS: There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes. There was low to moderate quality evidence of higher rates of adverse effects such as headache, vaginal bleeding, breast tenderness and skin reactions in the BHT group. There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects. Although all the included studies used unopposed estrogen, it is recommended best practice to use progestogen therapy in women with a ...
Source: Cochrane Database of Systematic Reviews - July 31, 2016 Category: Journals (General) Authors: Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR Tags: Cochrane Database Syst Rev Source Type: research

Reprint of: From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection.
This article is part of a Special Issue entitled SI:50th Anniversary Issue. PMID: 27317847 [PubMed - as supplied by publisher]
Source: Brain Research - June 14, 2016 Category: Neurology Authors: Engler-Chiurazzi EB, Singh M, Simpkins JW Tags: Brain Res Source Type: research

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Vaginal estradiol use and the risk for cardiovascular mortality
STUDY QUESTION Does the use of post-menopausal vaginal estradiol (VE) affect the mortality risk for coronary heart disease (CHD) and stroke. SUMMARY ANSWER The use of VE reduces the risk for cardiovascular mortality. WHAT IS KNOWN ALREADY A growing number of women use VE for post-menopausal genitourinary symptoms. Although this therapy is intended to have only local effects, estrogen is absorbed into the blood circulation and thus VE use may also have systemic effects. STUDY DESIGN, SIZE, DURATION We studied a nationwide cohort in Finland 1994–2009 during which post-menopausal women (n = 195 756) initiated the use...
Source: Human Reproduction - March 15, 2016 Category: Reproduction Medicine Authors: Mikkola, T. S., Tuomikoski, P., Lyytinen, H., Korhonen, P., Hoti, F., Vattulainen, P., Gissler, M., Ylikorkala, O. Tags: Puberty, Aging and HRT Source Type: research